What is the future of medtech in 2018?

Share

medtech future leap jump inspiration risk

[Photo by Jordan McQueen on Unsplash]

Some of the largest medtech companies showed in 2017 that they are ready to grow through embrace of the new healthcare ecosystem.

Medical device companies are putting greater emphasis on value-based arguments for their products and services. They’re putting more attention to clinical and economic research and adopting digital products that incorporate machine learning and data integration.

Questions, though, still remain as we enter 2018. The editors at MDO asked several experts – many at the recent DeviceTalks West in Orange County, Calif. – to weigh in on what they believe will happen in the coming year. Some offered insight into FDA’s future, as well as the future of global regulatory bodies. Others focused on how healthcare policies and patent law trends will impact medical device businesses. And some looked at technology, most importantly, the convergence of digital technology and device technology – and shared the trends they expect to see in the coming year.

Read on to discover the experts’ thoughts about important trends facing the industry.

Next>>

Managing editor Chris Newmarker contributed to this report.

Join the Best Minds in MedTech at DeviceTalks Minnesota!

textadimage This year’s DeviceTalks Minnesota features four tracks packed with expertly curated content created by the industry for the industry.

ECO-SYSTEM TRACK: focuses on issues impacting medtech companies across Minnesota and beyond. TECHNOLOGY TRACK: drills down on the hottest new tech that is changing medtech. REGULATORY 201 and CLINCAL 201 TRACKS: Hosted by Medical Alley and focuses on the most important trends in regulatory and clinical development.

Take a look at our full agenda.

Use the code "TRACKS" to save 15% on the cost of registration. 

REGISTER TODAY

Pages: 1 2 3 4 5 6 7 8

Comments

  1. Alok Sharma says:

    In the year 2018, device industry must cohesively work more with Pharma companies to add value to the life of the patients. The disease and the disease patterns are changing & so the long term outcomes. Doctors / practitioners/ Companies & regulatory authorities must look at the side effects of post implantation of a device and prescribe medications so that long term outcomes of the patients are better with low side effects. Not all patients globally have an insurance Cover. Adipose tissue derived autologous Stem Cells treatment must get speedy approvals from regulatory authorities.

Speak Your Mind

*